FINWIRES · TerminalLIVE
FINWIRES

Update: Northern Star Resources Should Launch Strategic Review, Explore Sale, Activist Investor Elliott Says; Shares Up 9%

By

(Updates to add stock movement in the headline and last paragraph)

Northern Star Resources (ASX:NST) should conduct a strategic review that includes a potential sale, alongside a search for a new CEO, to identify opportunities for operational improvements, shareholder Elliott Investment Management said Monday.

Elliott disclosed a stake of over AU$1 billion in Northern Star Resources, saying it wants to work with the company to maximize shareholder value.

"Northern Star's recent pattern of operational missteps, cost overruns and inconsistent strategic direction demands urgent action," Elliott said, adding that the company has underperformed its potential despite holding world-class gold assets.

The activist investor also urged the company to supplement its board with "fresh perspectives" to help guide the review and subsequent steps.

Elliott further alleged that Northern Star has "deeply inadequate disclosures compared to global senior peers." The company is likely to draw "significant strategic interest" if it explores a sale, Elliott said.

Northern Star Resources did not immediately reply to a request for comment from.

The company's shares rose around 9% in recent Tuesday trade.

Related Articles

Wire

Xometry Plans Offering of Class A Shares

Xometry (XMTR) said Monday it has started an underwritten public offering of $225 million of its Class A shares, subject to market conditions.Underwriters will be given a 30-day option to buy up to an additional $33.75 million of shares, the company said.Net proceeds from the planned offering are for working capital and general corporate purposes, Xometry said.Xometry shares were down past 9% in after-hours activity.

$XMTR
Wire

LXP Industrial Trust Revises 2026 Adjusted FFO Guidance

LXP Industrial Trust (LXP) said late Monday it now expects 2026 adjusted funds from operations per diluted share of $3.30 to $3.40 from $3.22 to $3.37 earlier.Analysts polled by FactSet expected $3.28.In May, the company acquired a 37-acre infill industrial redevelopment site in the South Airport submarket of Phoenix for $103 million, according to a statement.The site produces annual rent of $16.1 million, with 2% annual rent hikes, the company said.

$LXP
Wire

Abivax's Obefazimod Trial Meets Main Goal in Ulcerative Colitis; Shares Fall After Hours

Abivax SA (ABVX) said its Phase 3 maintenance trial evaluating obefazimod in adults with moderately to severely active ulcerative colitis met its primary endpointBoth the 25 mg and 50 mg doses also met all key secondary endpoints, including endoscopic improvement, endoscopic remission, corticosteroid-free clinical remission and sustained clinical remission, the company said Monday in a statement.Obefazimod demonstrated a favorable safety profile over the 44-week maintenance trial, with no new safety signals observed, the company said.Week-44 clinical remission rates were 50.8% with 25 mg and 51.3% with 50 mg, versus 10.4% for placebo, the company said.Abivax plans to submit a New Drug Application to the US Food and Drug Administration in Q4.Abivax shares fell 23% in after-hours trading.

$ABVX